Atossa Therapeutics, Inc. (ATOS) is a clinical-stage biopharmaceutical company committed to pioneering therapies that address unmet medical needs. Founded in 2009 and headquartered in Seattle, Washington, it is primarily focused on developing and marketing novel drugs in the areas of oncology, specifically breast cancer, and infectious diseases including COVID-19.
Atossa Therapeutics rides on its unique approach of locally administering therapeutics to targeted diseases, which helps maximize the effectiveness while minimizing systemic side effects. The company’s flagship Endoxifen therapy, a compound derived from tamoxifen, is aimed at transforming the treatment paradigm for breast cancer and other conditions. Atossa’s development efforts include the utilization of its patented intraductal microcatheter technology and its nasal spray technology.
The intraductal microcatheter technology is utilized in the delivery of pharmaceutics and therapeutics to the ducts in the breast, the place where breast cancer commonly originates. This technology enables effective and direct delivery, thereby reducing potential off-target effects and systemic toxicity.
Atossa is also aggressively pursuing the end of the COVID-19 pandemic, leveraging its nasal spray technology to administer AT-H201, a potential therapeutic to help improve lung function in hospitalized patients with a severe case of the disease. AT-H201 is currently undergoing both preclinical and clinical explorations.
What differentiates Atossa Therapeutics is its novel approach to addressing diseases that impact large patient populations globally, with unique delivery systems and proprietary treatments that could eventually change the adversities and outlook of these conditions. Its innovative therapeutics are not just potentials to pioneer uncharted territories in medicine, but are also aimed at elevifying the quality of life of the afflicted patient populations.
The company’s commitment to developing new treatment paradigms for significant health issues like breast cancer and COVID-19 has charted a unique path for it in the industry. As the company continues to focus on efficacy and affordability of its treatments, Atossa Therapeutics is steadily making strides in the field of healthcare, setting new benchmarks in patient care.